US researchers have made a discovery that might help doctors distinguish between benign and more aggressive forms of prostate cancer. The team reports that a difference in the geneticmake-up of prostate tumours could indicate it.…

Amgen Inc. (AMGN) said the U.S. Food and Drug Administration is aiming for next April to decide whether to approve its bone cancer drug to help reduce the risk of a type of prostate cancer from spreading to the bone. …

Scientists are constantly on the hunt for treatments that can selectively target cancercells, leaving other cells in our bodies unharmed. Now, Prof. Eytan Ruppin of Tel Aviv University's Blavatnik School of Computer Science.…

Prostate cancer is the second leading cause of cancer-related deaths in men, but one of the challenges in this disease has been the inability to differentiate between men who have aggressive tumors and those who have indolent tumors.…

Dr. David Samadi, Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center knows the wide range of emotions and fears that men with prostate cancer face.…

A new prostate screening test developed by AnalizaDx, Inc., a Cleveland-based biotech company, and studied by researchers at the Seidman Cancer Center at University Hospitals (UH) CaseMedical Center along with colleagues at the Cleveland.…

Real-time elastography (RTE) significantly improves detection of prostate cancer (PCa) and extracapsular extension compared with grey-scale ultrasonography (GSU), according to researchers. …